Avalo Therapeutics (AVTX) Set to Release Earnings This Friday

Avalo Therapeutics (NASDAQ:AVTX) is gearing up to announce its quarterly earnings report before the market opens on Friday, April 4th. Analysts predict that the company will report earnings of $0.58 per share for this quarter.

Avalo Therapeutics Stock Performance

On the trading day before the earnings announcement, Avalo Therapeutics shares opened at $8.73. The stock has shown notable volatility over the past year, with a low of $5.99 and a high of $34.46. Currently, its 50-day simple moving average stands at $7.59, while the 200-day average is at $9.13.

Recent Analyst Ratings

Avalo Therapeutics has been the focus of multiple research studies recently. On Thursday, March 20th, HC Wainwright maintained a "neutral" stance on the stock in their report. Meanwhile, Jefferies Financial Group initiated coverage by giving the company a "buy" rating and setting a price target of $23.00. Other analysts like Piper Sandler have also begun coverage with an "overweight" rating and a price target of $48.00. Additionally, Wedbush reiterated an "outperform" rating, setting their price target at $18.00. Stifel Nicolaus has rated Avalo Therapeutics as a "buy" with a price target of $36.00. Overall, one analyst recommends holding the stock, while six analysts suggest buying it. According to MarketBeat, Avalo Therapeutics currently holds a consensus rating of "Moderate Buy" with a price target averaging $33.00.

About Avalo Therapeutics

Avalo Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to developing therapies aimed at treating immune dysregulation in the United States. The company's pipeline includes AVTX-009, an Anti-IL-1ß monoclonal antibody currently in Phase I trials for inflammatory diseases, and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein targeted at disorders related to immune dysregulation.

Conclusion

Investors and analysts alike will be keenly watching for Avalo Therapeutics’ earnings report this Friday. The anticipated results may provide additional insights into the company's potential and performance in the biotechnology sector.

Earnings, Stocks, Analyst